María Pilar Garrido López-rekin lankidetzan egindako argitalpenak (15)

2022

  1. Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion

    Human Pathology Reports, Vol. 28

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

2019

  1. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review

    Respiratory Medicine Case Reports, Vol. 26, pp. 310-314

  2. High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features

    Cancers, Vol. 11, Núm. 1

2018

  1. Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples

    Biological Procedures Online, Vol. 20, Núm. 1

  2. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

    Clinical and Translational Oncology, Vol. 20, Núm. 4, pp. 443-447

  3. Proposal of the SEOM, SEAP and SEFH for the creation of a National Strategy for Precision Medicine in Cancer

    Revista Espanola de Patologia

2017

  1. Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: A position statement of SEOM, SEAP and SEFH

    Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 688-691

  2. Treating KRAS -mutant NSCLC: Latest evidence and clinical consequences

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 9, pp. 589-597

2016

  1. Necitumumab in squamous non-small-cell lung cancer: How to move forward?

    Annals of Oncology

2012

  1. A new multidisciplinary Spanish Working Group on Cancer Biomarkers: Presentation and aims

    Clinical and Translational Oncology

  2. Grupo de Trabajo Interdisciplinar sobre Biomarcadores en Cáncer SEAP-SEOM: Presentación y objetivos

    Revista Espanola de Patologia

2011

  1. Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico

    Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48

  2. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651